EMEA-002152-PIP02-17-M01 - paediatric investigation plan
Daratumumab
PIPHuman
Janssen-Cilag International N.V.
E-mail: nbuhl@its.jnj.com
Tel. +353 8574 46696
P/0206/2019: EMA decision of 12 June 2019 on the acceptance of a modification of an agreed paediatric investigation plan for daratumumab (Darzalex) (EMEA-002152-PIP01-17-M01)